中国介入心脏病学杂志2024,Vol.32Issue(5) :271-275.DOI:10.3969/j.issn.1004-8812.2024.05.007

重度主动脉瓣狭窄合并慢性冠状动脉疾病患者经导管主动脉瓣置换术同期/分期经皮冠状动脉介入治疗救治策略的研究进展

Research progress on treatment strategies for simultaneous/staged percutaneous coronary intervention in patients with severe aortic valve stenosis and chronic coronary artery disease undergoing percutaneous aortic valve replacement surgery

马玲 王婧雅 徐倩伟 余小林
中国介入心脏病学杂志2024,Vol.32Issue(5) :271-275.DOI:10.3969/j.issn.1004-8812.2024.05.007

重度主动脉瓣狭窄合并慢性冠状动脉疾病患者经导管主动脉瓣置换术同期/分期经皮冠状动脉介入治疗救治策略的研究进展

Research progress on treatment strategies for simultaneous/staged percutaneous coronary intervention in patients with severe aortic valve stenosis and chronic coronary artery disease undergoing percutaneous aortic valve replacement surgery

马玲 1王婧雅 1徐倩伟 1余小林2
扫码查看

作者信息

  • 1. 新疆医科大学研究生学院,新疆乌鲁木齐 830001
  • 2. 新疆维吾尔自治区人民医院心脏及泛血管诊疗中心,新疆乌鲁木齐 830001;新疆心脏血管稳态与再生医学研究重点实验室,新疆乌鲁木齐 830001
  • 折叠

摘要

目前,经导管主动脉瓣置换术(TAVR)已不仅仅是外科高危重度主动脉瓣狭窄(AS)患者的优选替代方案,中危和低危AS患者也有所获益.近1/2的AS患者合并冠状动脉疾病(CAD),因此在TAVR治疗重度AS合并CAD的患者中行经皮冠状动脉介入治疗(PCI)成为临床常见需求.当前TAVR与PCI孰先孰后亦或同期进行存在较大争议.本文将对行TAVR治疗的重度AS合并慢性CAD患者行PCI的时机进行综述.

Abstract

Currently,transcatheter aortic valve replacement(TAVR)is not only the preferred alternative for highrisk and severe aortic stenosis(AS)patients in surgery,but also benefits patients with moderate and lowrisk AS.Nearly half of AS patients have coronary artery disease(CAD),so percutaneous coronary intervention(PCI)has become a common clinical requirement in patients with severe AS combined with CAD treated with TAVR.There is significant controversy over which TAVR or PCI should be prioritized or conducted simultaneously.This article will review the timing of PCI treatment for severe AS patients with chronic CAD who undergo TAVR treatment.

关键词

主动脉瓣狭窄/经导管主动脉瓣置换术/经皮冠状动脉介入治疗

Key words

Aortic stenosis/Transcatheter aortic valve replacement/Percutaneous coronary intervention

引用本文复制引用

出版年

2024
中国介入心脏病学杂志
北京大学

中国介入心脏病学杂志

CSTPCD
影响因子:1.224
ISSN:1004-8812
段落导航相关论文